Slow Release T3 Starting Dose: A Research-Context Titration Guide

Research-community starting doses for slow release T3 vary more than newcomers expect, and the variation is not arbitrary. The entry point a research subject selects depends on which protocol framework they are operating within (Wilson's cyclic WT3 versus a longer-duration maintenance approach), what their baseline health status looks like (body weight, cortisol reserve, iron status), and whether they have any prior T3 exposure that has already established some receptor adaptation. Getting the starting dose wrong in either direction - too high and the research subject hits adrenergic side effects before establishing tolerability; too low and they waste weeks establishing a dose that could never produce a meaningful physiological signal - is one of the more preventable errors in SR-T3 research contexts. This guide maps the two main starting-dose lineages, the body-weight and cofactor adjustments the research community applies, and the titration tempo that follows each entry point.

Research framing. This article reviews slow release T3 starting-dose conventions and titration patterns discussed in research and bioenergetic-framework settings. It is not medical advice, and the dose figures cited are research-community reference points, not prescriptions. T3 products on this site are sold as research reference standards and are not approved for human consumption. See our research-use-only disclaimer for full terms.

Research Grade · Discreet Worldwide Shipping

SRT3-15 Slow Release T3 (15mcg, 100 capsules)

Buy Now →

The Two Starting-Dose Lineages: Wilson's WT3 vs Maintenance Protocols

The most important thing to understand about SR-T3 starting doses is that there is not one consensus entry point - there are two structurally distinct lineages, and they arrive at different starting doses for well-defined reasons rooted in protocol design, not in disagreement about pharmacology.

The Wilson's WT3 lineage starts at 7.5 mcg every 12 hours. The Wilson's Temperature Syndrome protocol, which is the most structured and documented SR-T3 research framework in use, establishes 7.5 mcg every 12 hours as the standard entry point. The rationale is not that 7.5 mcg every 12 hours produces a significant T3 effect in most research subjects - at 15 mcg total daily, it typically does not - but that the protocol is cyclic and designed to titrate upward to a temperature endpoint before systematically tapering. The starting dose in a cyclic protocol is the first rung of a titration ladder, and setting it low ensures the research subject can establish tolerability and a consistent dosing rhythm before any meaningful dose escalation begins. The 3-5 day dwell time between titration steps is built into the protocol structure from the outset.

Maintenance protocols often start at 15-25 mcg once daily. Research subjects using SR-T3 as a longer-duration maintenance intervention - either as T3 monotherapy or as an add-on to an existing T4 backbone - often start at a higher entry dose than the Wilson's WT3 lineage. The structural reason is straightforward: a maintenance protocol is not aiming to reach a temperature endpoint on a rapid staircase; it is aiming to establish a stable, well-tolerated dose that provides sustained T3 support without requiring the research subject to cycle on and off. Starting at 15 mcg once daily maps directly to the SRT3-15 capsule strength, which is the entry-strength reference standard for maintenance protocols. Research subjects adding SR-T3 to a T4 backbone sometimes start at 10-15 mcg once daily in the morning and add a second dose after 2-4 weeks of tolerance assessment; T3 monotherapy (without T4) starts more conservatively, typically at 7.5-15 mcg twice daily.

The key insight is that the different starting doses reflect different protocol structures, not different assessments of what SR-T3 can do. A Wilson's WT3 research subject who starts at 7.5 mcg every 12 hours will be titrating to doses substantially higher than 15 mcg total daily within a week or two; a maintenance-protocol research subject who starts at 15 mcg once daily is targeting a stable dose in the 15-50 mcg range depending on their response. The entry points are calibrated to where each protocol is going, not just to where it starts.

For a full treatment of the Wilson's WT3 cyclic framework, including the temperature endpoint, the rT3 dominance premise, and the weaning phase that follows effective titration, see the Wilson's T3 protocol guide.

Body-Weight Scaling: When Standard Starting Doses Are Wrong

The research community does not use formal weight-based dosing tables for SR-T3 - the variation in individual sensitivity, cofactor status, and baseline thyroid function is too large to support a strict mcg-per-kg formula. But body weight and lean mass are informally referenced as adjustments to the standard starting dose, and the adjustments are directionally consistent enough to function as practical guidance.

Research subjects under 60 kg: start at half the standard dose. At lower body weight, the distribution volume for liothyronine is proportionally smaller, and the standard starting dose produces a higher effective concentration per kilogram of receptor-bearing tissue. The research community convention for smaller-framed research subjects - roughly those under 60 kg - is to begin at half the standard entry for the protocol in use. For Wilson's WT3, that means 3.75 mcg every 12 hours rather than 7.5 mcg; for maintenance protocol, it means 7.5 mcg once daily rather than 15 mcg. The dose can be titrated at the same tempo as the standard protocol once tolerability is established.

Practically, the 3.75 mcg starting dose presents a compounding challenge: standard SR-T3 capsule strengths begin at 7.5 mcg. Research subjects targeting a 3.75 mcg entry dose typically open a 7.5 mcg capsule and split the powder - a workaround that the research community acknowledges introduces accuracy variability but is the practical approach at sub-standard-capsule dose levels.

Research subjects over 90 kg: standard starting dose, but titrate faster. Larger-framed research subjects carry more T3-receptor-bearing tissue and typically find that the standard starting dose is subtherapeutic for a longer duration than it is for subjects in the standard weight range. The standard recommendation is to begin at the same starting dose as the protocol calls for - not to start higher, which would compress the tolerability assessment window - but to move through titration steps at the faster end of the permitted range. For Wilson's WT3, that means advancing every 3 days rather than every 5; for maintenance protocol, advancing every 7-10 days rather than 14. The goal is to reach the effective range faster without skipping the early dose levels entirely.

The informal weight thresholds of 60 kg and 90 kg are heuristics, not pharmacokinetically derived cutoffs. Lean body mass is more relevant than total weight - a 90 kg research subject with high body fat carries less T3-receptor-bearing tissue than a 90 kg research subject with high lean mass, which affects dose requirements in the opposite direction from raw weight. The adjustment is a starting-point estimate, not a precision calculation.

When to Start Lower Than the Standard Dose

Three specific baseline conditions warrant starting below the protocol's standard entry dose - not just adjusting for body weight, but genuinely reducing the starting point to accommodate a physiological vulnerability that would otherwise produce disproportionate side effects at the standard dose.

Low baseline morning cortisol (below 10 mcg/dL): start at half dose, address cortisol first. The interaction between T3 and the HPA axis is well-established: T3 amplifies cortisol receptor sensitivity and accelerates cortisol clearance. In a research subject with adequate cortisol reserve, this interaction produces a synergistic metabolic response. In a research subject with a low cortisol baseline, the same interaction accelerates cortisol depletion, producing a compensatory adrenal response that can present as anxiety, palpitations, fatigue, or temperature instability - symptoms that are often misattributed to T3 excess when the actual driver is cortisol insufficiency. Starting at half the standard dose in this population reduces the cortisol-depletion rate while the research subject addresses the underlying cortisol deficit. Advancing to the standard starting dose before the cortisol picture improves typically does not produce better outcomes and carries a higher risk of the adrenal-response pattern. See the full cortisol-T3 interaction analysis in the T3 adrenal fatigue and cortisol connection guide.

Severe iron deficiency (ferritin below 30 ng/mL): start at half dose, prioritize iron repletion. Iron deficiency impairs nuclear T3 receptor function at the cellular level, independent of serum T3 concentration. A research subject with ferritin below 30 ng/mL is operating with a T3 receptor system that cannot respond normally to circulating T3 - meaning higher SR-T3 doses will produce more circulating T3 without producing more receptor activation, while potentially driving adrenergic symptoms and cardiovascular stimulation that are not offset by the metabolic benefits. Starting at half the standard dose in iron-deficient research subjects limits the mismatch between circulating T3 and receptor responsiveness while iron repletion is underway. The research community's functional threshold for T3 receptor activation is typically cited at ferritin above 70-80 ng/mL - considerably above the conventional deficiency cutoff of 10-12 ng/mL - which means many research subjects who are "not anemic" by standard labs are still significantly iron-deficient by functional thyroid-research standards.

Sensitive cardiovascular history or pre-existing arrhythmia and severe anxiety: start at quarter dose, titrate cautiously. Research subjects with documented arrhythmia, resting tachycardia above their individual baseline, severe anxiety disorders, or other cardiovascular vulnerabilities require a more conservative entry than either the weight-adjusted or cortisol-adjusted starting points described above. The research community convention for this population is to begin at roughly a quarter of the standard protocol starting dose - for Wilson's WT3, that means 3.75 mcg once daily (not twice daily) before advancing to twice-daily dosing; for maintenance protocol, 3.75-7.5 mcg once daily with very slow titration. Monitoring heart rate at each titration step is standard practice in this population. Any new or worsening arrhythmia warrants dose hold and clinical evaluation before further titration.

The Titration Tempo: How Fast to Increase

The titration tempo - the frequency and magnitude of dose increments - differs between the Wilson's cyclic protocol and the maintenance protocol, and the difference is substantial enough to matter for practical planning.

Wilson's WT3 cyclic protocol: increase by 7.5 mcg per dose every 1-3 days. The Wilson's protocol is designed to move through titration steps relatively aggressively, using oral body temperature as the real-time endpoint rather than labs or symptom clusters that take weeks to reflect dose changes. The standard increment is 7.5 mcg per dose per step - so a research subject at 7.5 mcg every 12 hours (15 mcg total daily) advances to 15 mcg every 12 hours (30 mcg total daily) at day 3-5, then to 22.5 mcg every 12 hours at day 6-10, and so on up the titration ladder. The 3-day minimum between steps is a safety buffer - it allows the cardiovascular and adrenergic response to each new dose to stabilize before another increment is added. Some Wilson's protocol practitioners permit advancing every 1-2 days if temperature response is clear and no side effects are present; the 3-5 day window is a common practical range rather than a fixed rule.

Moving faster than the 1-3 day minimum creates the risk of dose-stacking: T3 levels climb before the prior-step adaptation is complete, compressing the tolerability assessment window and making it difficult to identify which step is driving any side effects that emerge.

Maintenance protocol: increase by 7.5-15 mcg per dose every 7-14 days. The maintenance protocol uses a much more conservative titration cadence because the goal is not to reach a temperature endpoint as quickly as possible - it is to find the lowest effective stable dose with the best tolerability profile. The longer dwell time at each maintenance dose level allows labs (Free T3, TSH) to reach a new equilibrium; TSH suppression in particular has a multi-week pharmacokinetic lag that makes dose assessment at shorter intervals unreliable. For research subjects starting at 15 mcg once daily, the next step is typically 22.5 mcg or 30 mcg once daily at week 2 or later, depending on symptom response and tolerability. Research subjects adding a second daily dose move to twice-daily dosing before increasing total dose per-administration.

The 7.5 mcg increment remains the standard titration step in both protocol contexts because it maps to the available capsule strengths and provides the smallest meaningful dose increment that compounded SR-T3 can reliably deliver.

The Pharmacokinetic Argument for SR-T3 Starting Doses

The starting-dose framework described in the sections above assumes the research subject is using sustained-release T3. This assumption matters, because the dose conventions for immediate-release T3 (Cytomel or generic liothyronine) are meaningfully different - and understanding why illuminates the pharmacokinetic logic underlying SR-T3 starting doses.

Immediate-release Cytomel starting doses are conventionally lower than SR-T3 starting doses: clinical practice guidelines cite 5-10 mcg total daily as the standard Cytomel entry, with cautious titration in 5 mcg steps. The reason is the peak-trough pharmacokinetic profile. Immediate-release liothyronine produces a serum peak at roughly 2 hours post-dose, with the peak concentration representing a 2-4x elevation above the baseline T3 level before the curve begins to fall. This acute peak drives stronger cardiovascular receptor stimulation per microgram of T3 than the same dose spread over a 4-8 hour release window. The result is that Cytomel starting doses need to be lower not because the total daily T3 exposure is different, but because the peak concentration per dose is higher.

SR-T3's flatter curve changes this calculation. With the dose released over 4-8 hours rather than concentrated into a 2-hour peak, the cardiovascular receptor stimulation per microgram of T3 is substantially attenuated. A 15 mcg SR-T3 dose produces a much gentler serum peak than a 15 mcg Cytomel dose - the area under the curve (total T3 exposure) is comparable, but the peak-to-trough ratio is fundamentally different. This is why SR-T3 starting doses can begin at 7.5-15 mcg per dose with tolerability comparable to Cytomel starting doses of 5-10 mcg: the pharmacokinetic profile, not the total T3 content, is what determines the acute adrenergic response.

The practical implication is that research subjects transitioning from Cytomel to SR-T3 should not assume a 1:1 dose equivalence at the starting-dose level. Because the peak is lower with SR-T3, some research subjects find they require a slightly higher total daily dose to achieve equivalent effect compared to the immediate-release they were using previously. Conversely, research subjects starting SR-T3 de novo who have read Cytomel-based dosing guidance and assumed SR-T3 would require similar caution at 5-10 mcg total daily often find the lowest SR-T3 capsule strength (7.5 mcg every 12 hours) is well-tolerated on day one.

For the full pharmacokinetic comparison between immediate-release and sustained-release T3 - including the HPMC matrix mechanism, the AUC equivalence data, and why the cardiovascular receptor stimulation difference is not just a theoretical concern - see the sustained release T3 complete guide. Research-grade SR-T3 at the standard maintenance starting strength is available as SRT3-15 Slow Release T3 (15mcg, 100 capsules); the Wilson's SR-T3 Combo Kit covers the full Wilson's WT3 capsule strength range for research subjects following the cyclic titration protocol.

Starting-Dose Reference Table

Reference to the Pillar's Troubleshooting Framework

Starting doses are the most consequential single decision in an SR-T3 research protocol, but they are not the last decision. A research subject who establishes a well-chosen starting dose and titrates at an appropriate tempo will still encounter the full range of SR-T3 response patterns - some productive, some requiring adjustment - as dose escalation proceeds.

If starting-dose adverse effects emerge - anxiety on the first or second dose, palpitations during the first titration step, headache on waking, or disrupted sleep following the evening dose - these are not automatically signals to abandon the protocol or conclude the research subject is "sensitive to T3." The slow release T3 dosing and troubleshooting complete guide provides the triage framework for distinguishing dose-related side effects from cofactor-deficiency responses from timing errors - and for deciding whether to hold, reduce, or simply adjust the schedule before drawing conclusions about tolerability.

Two of the most common starting-dose-specific adverse effects each have dedicated spoke posts in the cluster:

• Anxiety appearing at the starting dose or first titration step is typically a cortisol co-activation pattern, not direct T3 excess. The mechanism and adjustment protocol are covered in T3 anxiety - mechanism and research-community adjustments.

• Palpitations at the starting dose or during early titration steps are the most common cardiovascular presentation at this stage, and distinguishing T3-driven palpitations from iron-deficiency palpitations (a common comorbidity in the chronic-illness research population) is a critical first diagnostic step. Full causes and pharmacokinetic analysis: T3 heart palpitations - causes and pharmacokinetics.

What Research Has and Hasn't Established

Established:

Liothyronine starting-dose conventions are documented in clinical practice. The pharmacokinetics of immediate-release liothyronine - including the 2-hour peak, the 24-hour half-life, and the cardiovascular receptor sensitivity to peak concentration - are well-characterized in the literature. Sustained-release T3 formulations produce a demonstrably flatter serum curve than immediate-release liothyronine, which is the pharmacokinetic basis for the formulation existing at all. Body-weight scaling of thyroid hormone replacement has a plausible pharmacokinetic basis and is referenced in clinical practice guidance, though the evidence is more robust for T4 than for T3 specifically. The thyroid hormone-cortisol axis interaction - including T3's effect on cortisol receptor sensitivity and clearance - is well-established in the endocrinological literature.

Hypothesis:

The bioenergetic-research community starting-dose framework - specifically the distinction between the Wilson's WT3 7.5 mcg twice-daily entry and the maintenance-protocol 15 mcg once-daily entry - is research-community convention derived from clinical experience within these frameworks, not a result of randomized controlled trials comparing alternative starting doses. The body-weight adjustment thresholds (60 kg and 90 kg) are pragmatic heuristics, not pharmacokinetically derived cutoffs from published dose-finding studies. The cortisol and iron adjustment criteria reflect mechanistic plausibility and community experience, not prospective evidence from trials that enrolled low-cortisol or iron-deficient T3 research subjects as a defined population.

Not endorsed by mainstream endocrinology:

The bioenergetic-research starting-dose framework - particularly the maintenance-protocol starting doses of 15-25 mcg once daily and the rapid titration tempo of the Wilson's WT3 cyclic protocol - operates outside the scope of mainstream endocrinology guidelines for liothyronine use. Standard clinical guidelines for T3 therapy (where T3 is used at all in conventional practice) typically recommend lower starting doses and slower titration than either protocol context described in this guide. Research subjects should be aware that the research-community framework described here is not a mainstream clinical guideline and does not have the endorsement of regulatory bodies or major endocrinology societies.

Frequently Asked Questions

What is the starting dose for slow release T3?

The research-community starting dose depends on which protocol the research subject is following. For the Wilson's WT3 cyclic protocol, the standard entry is 7.5 mcg every 12 hours (15 mcg total daily). For maintenance protocols - particularly when SR-T3 is being used as a longer-duration intervention rather than a cyclic rT3-clearing approach - a common starting dose is 15 mcg once daily in the morning, with the option to add a second dose after 2-4 weeks. Research subjects with low cortisol, iron deficiency, cardiovascular sensitivity, or low body weight start at lower entry points as described in the sections above.

How is Wilson's WT3 starting dose different from maintenance starting dose?

Wilson's WT3 starts at 7.5 mcg every 12 hours because the protocol is cyclic: the goal is to titrate upward quickly to a temperature endpoint, then taper systematically. The low starting dose establishes the dosing rhythm and confirms tolerability before the rapid titration ladder begins. Maintenance protocols start at 15 mcg once daily because the goal is stable longer-duration support rather than cyclic rT3 clearance - the starting dose is already close to a therapeutically relevant range and will be titrated upward more slowly over weeks.

Should I start at a lower dose if I have low cortisol?

Yes. A morning cortisol below roughly 10 mcg/dL (or a clinical picture consistent with low cortisol reserve) warrants starting at half the standard protocol entry dose, and prioritizing cortisol support before advancing to the standard starting dose. T3 amplifies cortisol receptor sensitivity and accelerates cortisol clearance; starting at full dose in a low-cortisol research subject typically drives an adrenal-response pattern that presents as anxiety, palpitations, or fatigue and is frequently misread as T3 intolerance. See the T3 adrenal fatigue and cortisol connection guide for the full mechanism.

How fast can I titrate slow release T3?

The titration tempo depends on the protocol. Wilson's WT3 advances by 7.5 mcg per dose every 3-5 days (some practitioners permit every 1-3 days if response and tolerability are clear). Maintenance protocols advance by 7.5-15 mcg per dose every 7-14 days, allowing labs and symptoms time to reflect the new dose level before the next increment. Moving faster than these tempos compresses the tolerability assessment window and creates dose-stacking risk. Moving substantially slower than the maintenance tempo is not harmful but may delay identifying the effective dose.

Does body weight affect the starting dose?

Yes, informally. Research subjects under 60 kg are typically advised to start at half the standard protocol entry dose due to the smaller T3 distribution volume. Research subjects over 90 kg start at the standard dose but are typically advised to move through titration steps at the faster end of the permitted range, because they carry more receptor-bearing tissue and may require higher absolute doses to reach a therapeutic effect. These thresholds are practical heuristics rather than pharmacokinetically validated cutoffs.

Is SR-T3 starting dose different from Cytomel starting dose?

Yes, and the pharmacokinetic reason is important. Immediate-release Cytomel starting doses are conventionally lower (5-10 mcg total daily) because the 2-hour peak concentration produces stronger acute cardiovascular receptor stimulation per microgram than SR-T3's 4-8 hour release profile. SR-T3's flatter curve allows higher starting total daily doses at equivalent tolerability. Research subjects transitioning from Cytomel to SR-T3 should not assume a 1:1 dose equivalence at the starting-dose level - the effective dose may shift, and the tolerability profile at a given total daily dose is typically better with SR-T3.

What if I have anxiety on my starting dose?

Anxiety at the starting dose or during the first titration step is the most common early adverse effect in SR-T3 research contexts, and it usually reflects a cortisol co-activation pattern rather than direct T3 excess. The clinical picture is T3 amplifying cortisol receptor sensitivity in a research subject whose cortisol baseline is insufficient to handle the amplification without producing an adrenal response perceived as anxiety. The first step is to hold the current dose for 3-5 days and assess whether the anxiety resolves as adaptation occurs, rather than immediately reducing. If it persists, a dose reduction and cortisol assessment are warranted. The full mechanism and adjustment protocol are in the dedicated cluster post on T3 anxiety - mechanism and research-community adjustments.

How do I know my starting dose is right?

The starting dose itself is not the primary endpoint - it is a launching point. The signals that the starting dose is appropriate are negative ones: no adrenergic side effects (no significant anxiety, no palpitations, no sleep disruption), a tolerable first 3-7 days, and a clear path to titration. Positive effects at the starting dose level are uncommon in the Wilson's WT3 lineage (7.5 mcg every 12 hours is a sub-therapeutic dose for most research subjects) and modest in maintenance-protocol research subjects at 15 mcg once daily. The effective dose - where symptom response, temperature normalization, or lab markers reflect genuine T3 effect - is typically several titration steps above the starting dose. Expecting a strong response at the starting dose and reducing when it does not appear is a common reason research subjects abandon the protocol before reaching a dose level with meaningful signal.

Closing Note

The starting dose is the most durable decision in an SR-T3 research protocol: getting it right establishes the tolerability baseline and the titration ladder; getting it wrong either delays the protocol (if too conservative) or compresses the window for identifying genuine dose-related problems (if too aggressive). The framework in this guide - Wilson's WT3 at 7.5 mcg every 12 hours, maintenance protocol at 15 mcg once daily, with downward adjustments for low body weight, low cortisol, iron deficiency, and cardiovascular sensitivity - represents the research-community consensus starting point as of this writing.

What happens after the starting dose is where the protocol gets more complex, and where the troubleshooting framework matters. The slow release T3 dosing and troubleshooting complete guide covers the full arc from titration to timing to missed-dose protocol to the six explanations for non-response. Research-grade SRT3-15 Slow Release T3 (15mcg, 100 capsules) is the reference product for maintenance-protocol starting doses; the full SR-T3 strength range and combination products are available in the catalog. All compounds are sold strictly for laboratory research and are not approved for human consumption.